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Non-Specialty Specialty
April 2016
Drug Name: Ocrelizumab
Manufacturer: Genentech
Indication: RRMS and PPMS
Formulation: Intravenous infusion
Phase III
Drug Name: Atezolizumab
Manufacturer: Genentech
Indication:  mUC
Formulation: Intravenous infusion
Ocrelizumab is an investigational, humanized 
monoclonal antibody designed to selectively target 
CD20-positive B cells, which are key contributors to 
myelin and axonal damage in patients with multiple 
sclerosis. Ocrelizumab is being studied for the 
treatment of relapsing-remitting multiple sclerosis 
(RRMS) and primary progressive multiple sclerosis 
(PPMS).
Ocrelizumab was evaluated in three Phase III 
randomized, double-blind studies, including OPERA 
I and OPERA II in RRMS, and ORATORIO in PPMS. 
In OPERA I and OPERA II (N=1,656), treatment 
with ocrelizumab resulted in 46 and 47 percent 
reductions in annualized relapse rate, respectively, 
compared to treatment with Rebif® (interferon β-1a) 
over two years (P<0.0001 for both). In ORATORIO 
(N=732), treatment with ocrelizumab reduced the 
risk of clinical disability progression by 24 percent, 
sustained for at least 12 weeks, as measured by 
the Expanded Disability Status Scale, compared to 
placebo over two years (P=0.0321). Treatment with 
ocrelizumab also resulted in a statistically signifi cant 
reduction in the risk of clinical disability progression 
by 25 percent for at least 24 weeks, time to walk 
25 feet by 29 percent, volume of hyperintense T2 
lesions by 3.4 percent, and rate of whole brain 
volume loss by 17.5 percent compared to placebo 
over 120 weeks.
If approved, ocrelizumab may offer the fi rst 
treatment option for PPMS and an additional 
treatment option for RRMS. A Biologics License 
Application (BLA) submission is planned for 2016.
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Atezolizumab is a monoclonal antibody that 
inhibits the programmed death ligand-1 (PD-L1), 
resulting in the activation of thymus (T)-cells 
against tumor cells. Atezolizumab is currently being 
investigated for the treatment of patients with 
locally advanced or metastatic urothelial carcinoma 
(mUC) whose disease progressed during or after 
standard treatments.
In the open-label, single-arm Phase II IMvigor 
210 trial (N=310), patients with locally advanced 
or mUC, with or without PD-L1 expression, and 
whose disease progressed during or after previous 
treatment with a platinum-based regimen, received 
atezolizumab 1,200 mg intravenous (IV) once every 
three weeks until loss of clinical benefi t. After 
a median follow-up of 11.7 months, the median 
overall survival (OS) was 11.4 months in patients 
with higher PD-L1 expression (95 percent CI 9.0 to 
not estimable) and 7.9 months in the overall study 
population (95 percent CI 6.6 to 9.3). Additionally, 
15 percent of patients in the overall study group and 
26 percent of patients with medium or high PD-L1 
expression achieved a reduction in tumor burden 
(95 percent CI 11 to 19 and 95 percent CI 18 to 36, 
respectively). The median duration of response 
was not reached, with 84 percent of patients 
experiencing an ongoing response at follow-up. 
If approved, atezolizumab may offer a novel 
approach to the treatment of locally advanced or 
mUC. This agent is also being evaluated for use in 
kidney, breast, and lung cancer. Atezolizumab was 
granted Priority Review status with a Prescription 
Drug User Fee Act (PDUFA) date of Sep. 12, 2016.
BLA
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Drug Name:  Pimavanserin
Manufacturer: Acadia
Indication: PDP
Formulation: Oral tablet
NDA
Drug Name: Plecanatide
Manufacturer: Synergy
Indication: CIC                  
Formulation: Oral tablet
Drug Name: Romosozumab
Manufacturer: Amgen and UCB
Indication: Osteoporosis
Formulation: Subcutaneous injection
Phase III
Nuplazid™ (pimavanserin), a selective 
5-HT2A inverse agonist, is being investigated 
for the treatment of Parkinson’s disease 
psychosis (PDP).
The Phase III -020 Study (N=185) 
investigated treatment with pimavanserin 40 
mg daily compared to placebo. Pimavanserin 
recipients experienced a greater decrease 
in Parkinson’s disease-adapted Scale for 
Assessment of Positive Symptoms Scores 
compared to placebo (-5.79 and -2.73, 
respectively, 95 percent CI -4.91 to -1.20, 
P=0.001). A greater improvement in 
psychosis from baseline was reported with 
pimavanserin compared to placebo (37 
versus 14 percent, respectively, P=0.0006). 
Treatment with pimavanserin resulted in 
greater improvements in the Clinical Global 
Impression-Severity and Improvement 
scores compared to placebo (-0.58 and 
-0.67, P=0.0007 and P=0.0011, respectively). 
In addition, caregivers of subjects in the 
pimavanserin group reported a signifi cant 
improvement in sleep and daytime 
wakefulness compared to placebo. 
If approved, pimavanserin may provide 
the fi rst Food and Drug Administration 
(FDA)-approved treatment option for 
PDP. On March 29, 2016, an FDA Advisory 
Committee voted 12 to 2 that the benefi ts 
of treatment with pimavanserin outweighed 
the risks; however, they did not formally 
make a recommendation for or against 
approval. Pimavanserin was granted the 
Breakthrough Therapy designation and 
Priority Review status with a PDUFA date of 
May 1, 2016.
Romosozumab is a monoclonal 
antibody that is being studied for the 
treatment of osteoporosis. Romosozumab 
inhibits sclerostin, thereby increasing bone 
formation and decreasing bone breakdown.
The randomized, open-label Phase III 
STRUCTURE trial (N=436) compared the 
safety and effi cacy of romosozumab to 
Forteo® (teriparatide) in postmenopausal 
women who were previously treated with 
bisphosphonates. Monthly treatment with 
romosozumab 210 mg resulted in a greater 
average change in hip bone mineral density 
over 12 months compared to daily Forteo® 
(teriparatide) 20 mcg injections. The 
incidence of adverse events was similar 
between groups, with the most common 
adverse events in the romosozumab group 
being nasopharyngitis, arthralgia, back 
pain, headache, and falls. 
The randomized, double-blind, parallel-
group Phase III FRAME study (N=7,180) 
evaluated treatment with romosozumab 
for reducing the risk of new vertebral 
fractures in postmenopausal women 
with osteoporosis over 12 and 24 months 
compared to placebo, followed by open-
label treatment with Prolia® (denosumab) 
in both groups. Monthly treatment with 
romosozumab resulted in a statistically 
signifi cant 73 percent reduction in relative 
risk for vertebral fracture through 12 
months compared to placebo, and the 
effect was sustained through 24 months 
during the open-label Prolia® (denosumab) 
phase (75 percent reduction).
If approved, romosozumab could 
provide a novel monthly treatment option 
for women at high risk of fractures. A BLA 
submission is planned for 2016.
Plecanatide is a uroguanylin analog that 
stimulates guanylate cyclase-c, thereby 
increasing fl uid movement. This agent is 
being studied for the treatment of chronic 
idiopathic constipation (CIC) and irritable 
bowel syndrome with constipation.
The safety and effi cacy of plecanatide 
were evaluated in two Phase III clinical trials 
(N=2,683) which compared plecanatide 3 mg 
or 6 mg to placebo for the treatment of CIC. 
The primary and secondary endpoints for 
both studies were durable overall response 
and stool consistency. 
 In the fi rst study, the primary endpoint 
of durable overall response was achieved by 
21.0 and 19.5 percent of plecanatide 3 mg 
and 6 mg recipients, respectively, compared 
to 10.2 percent with placebo (P<0.001 for 
both). The average increases in Bristol 
Stool Form Scale (BSFS) scores were 1.53 
and 1.52 for the plecanatide 3 mg and 6 mg 
recipients, respectively, compared to 0.77 
with placebo (P<0.001 for both). 
In the second study, durable overall 
response was achieved by 20.1 and 20.0 
percent of plecanatide 3 mg and 6 mg 
recipients, respectively, compared to 12.8 
percent with placebo (P=0.004 for both). 
The average increases in BSFS were 1.49 
and 1.50 for the plecanatide 3 mg and 6 mg 
recipients, respectively, compared to 0.87 
with placebo (P<0.001 for both).
If approved, this agent may provide an 
additional treatment option for CIC with 
an improved tolerability profi le compared 
to other available agents. An NDA was 
submitted in January 2016.
NDA
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Drug Name: Venetoclax
Manufacturer: Genentech and AbbVie
Indication: Relapsed/refractory CLL
Formulation: Oral tablet
NDA
Drug Name: Sofosbuvir/velpatasvir
Manufacturer: Gilead Sciences
Indication: HCV infection
Formulation: Oral tablet
Drug Name: Sarilumab
Manufacturer: Regeneron and Sanofi 
Indication: Moderate-to-severe RA
Formulation: Subcutaneous injection
BLA
Venetoclax, an oral B-cell lymphoma-2 
inhibitor, is currently being investigated 
for the treatment of various cancer types, 
including chronic lymphocytic leukemia 
(CLL) and acute myeloid leukemia. 
The pivotal Phase II, open-label, single 
arm M13-982 study (N=107) met its primary 
endpoint of overall response rate (ORR) 
by demonstrating a clinically meaningful 
reduction in the number of cancer cells 
in 79.4 percent of patients with relapsed 
or refractory CLL with the 17p (petit arm 
of chromosome 17) deletion who received 
treatment with venetoclax.
The one-year progression-free 
survival (PFS), OS, and complete response 
rates were 72.0, 86.7, and 7.5 percent, 
respectively. The most common serious 
adverse events were fever, low red blood 
cell count, pneumonia, and low white 
blood cell count with fever. The study also 
included a safety expansion cohort (N=50), 
the results of which demonstrated that the 
safety of venetoclax was similar to what 
was observed in previous studies.
The FDA granted venetoclax the 
Breakthrough Therapy designation for the 
treatment of relapsed or refractory CLL in 
patients with the 17p deletion and Priority 
Review status for the treatment of CLL in 
patients who have received at least one 
prior therapy, including those with the 17p 
deletion.
If approved, venetoclax may provide 
a novel treatment option for relapsed 
or refractory cases of CLL with the 17p 
deletion. This agent is also being studied 
in combination with anti-CD20 monoclonal 
antibodies. An FDA decision is expected in 
the fi rst half of 2016. 
Sarilumab is a fully human monoclonal 
antibody that works by inhibiting the 
interleukin-6 receptor. It is currently being 
studied for the treatment of moderate-to-
severe rheumatoid arthritis (RA).
The Phase III SARIL-RA-TARGET 
trial (N=546) compared treatment with 
sarilumab 200 mg or 150 mg every two 
weeks to placebo, in combination with 
conventional disease-modifying anti-
rheumatic drug therapy, in patients who had 
an inadequate response or intolerance to 
tumor necrosis factor (TNF)-α inhibitors. Both 
sarilumab groups experienced improvement 
in physical function, as measured by mean 
change from baseline in Health Assessment 
Questionnaire-Disability Index at week 12 
(P=0.0004 and P=0.0007, respectively) and 
signs and symptoms of RA, as measured 
by the proportion of patients achieving a 
20 percent improvement in the American 
College of Rheumatology score at week 24 
compared to placebo (P<0.0001 for both).
The Phase III SARIL-RA-MONARCH trial 
(N=369), which compared sarilumab 200 
mg every two weeks to adalimumab 40 mg 
every two weeks, found that treatment 
with sarilumab was associated with a 
signifi cant improvement in Disease Activity 
Score 28-Erythrocyte Sedimentation Rate at 
24 weeks compared to adalimumab (-3.25 
versus -2.22, respectively, P<0.0001).
Sarilumab may offer another treatment 
option for patients who had an inadequate 
response to TNF-α inhibitors, a current 
standard-of-care therapy. An FDA decision 
is expected by Oct. 30, 2016.
Sofosbuvir/velpatasvir is a fi xed-dose 
combination of Sovaldi® (sofosbuvir), a 
nucleotide analog nonstructural protein 
5B (NS5B) polymerase inhibitor, and 
velpatasvir, an investigational pan-genotypic 
nonstructural protein 5A (NS5A) inhibitor. 
This agent is currently being studied for the 
treatment of genotype 1 through 6 chronic 
hepatitis C virus (HCV) infection. 
The randomized, double-blind Phase 
III ASTRAL-1 study (N=624) compared 
sofosbuvir 400 mg/velpatasvir 100 mg once 
daily for 12 weeks to placebo in patients 
with HCV genotypes 1a, 1b, 2, 4, 5, or 6. 
The prevalence of these genotypes among 
patients receiving active treatment was 34, 
19, 17, 19, 6, and 7 percent, respectively.
Of the active treatment recipients 
(N=624), 68 percent were treatment-naïve 
and 19 percent had compensated cirrhosis. 
Sustained virologic response at 12 weeks 
post-treatment (SVR12) was achieved in 99 
percent of patients overall and ranged from 
97 to 100 percent, depending on genotype 
(95 percent CI 98 to >99). In two additional 
Phase III studies, ASTRAL-2 and ASTRAL-3, 
treatment with this regimen in HCV 
genotype 2 and 3 infection resulted in SVR12 
rates of 99 and 95 percent, respectively.
The once-daily interferon- and ribavirin-
free regimen of sofosbuvir/velpatasvir offers 
high cure rates in all six HCV genotypes 
which is an advantage over currently 
available regimens. The FDA granted the 
Breakthrough Therapy designation to this 
agent for the treatment of HCV and an FDA 
decision is expected by June 28, 2016. 
NDA
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Gilotrif® (afatinib)
The Phase III, open-label LUX-Lung 8 trial (N=795) 
compared treatment with afatinib 40 mg daily to 
erlotinib 150 mg daily in adults with stage IIIB or IV 
squamous cell carcinoma of the lung who progressed 
following at least four cycles of platinum-based 
chemotherapy. Patients treated with afatinib achieved 
an OS of 7.9 months compared to 6.8 months with 
erlotinib (HR 0.81, 95 percent CI 0.69 to 0.95, P=0.0077) 
and a PFS of 2.6 months compared to 1.9 months, 
respectively (HR 0.81, 95 percent CI 0.69 to 0.96, 
P=0.0103). An FDA decision is expected in the fi rst half 
of 2016.
Stelara® (ustekinumab)  
The Phase III UNITI-2 trial (N=628) compared treatment 
with ustekinumab 130 mg or 6 mg/kg IV to placebo 
in adults with moderately-to-severely active Crohn’s 
disease who had previously failed or were intolerant 
to corticosteroids or immunomodulators. At week six, 
clinical response was achieved by 51.7, 55.5, and 28.7 
percent of patients in the ustekinumab 130 mg, 6 mg/
kg, and placebo groups, respectively (P<0.001). At week 
eight, clinical remission was achieved by 30.6, 40.2, and 
19.6 percent of patients in the ustekinumab 130 mg,     
6 mg/kg, and placebo groups, respectively (P<0.009). An 
FDA decision is expected in the second half of 2016.
•  Crestor® (rosuvastatin calcium)
     5/2016       
      
•  Cubicin®  (daptomycin)
     6/2016
      
•  Nuvigil® (armodafi nil)
     6/2016       
  
•  Ziana® (clindamycin phosphate/
     tretinoin)
     7/2016
     
•  Azor® (olmesartan/amlodipine)
     10/2016
•  Benicar® (olmesartan)     
     10/2016
•  Benicar HCT® (olmesartan/
     hydrochlorothiazide)
     10/2016 
•  Seroquel XR® (quetiapine
     extended-release)
      11/2016
KyndrisaTM (drisapersen)
On Jan. 14, 2016, BioMarin Pharmaceutical 
Inc. announced that the FDA issued a complete 
response letter declining approval of the NDA 
for drisapersen. Drisapersen is currently being 
studied for the treatment of Duchenne muscular 
dystrophy that is amenable to exon 51 skipping. 
The complete response letter indicated that 
the NDA was not accepted because the standard 
of substantial evidence of effectiveness was 
not met and the FDA requested the completion 
of another trial before the drug would be 
reconsidered for approval. The manufacturer 
announced its intention to work with the FDA to 
determine the appropriate next steps. 
Opdivo® (nivolumab)
On Nov. 27, 2015, Bristol-Myers Squibb 
announced that the FDA issued a complete 
response letter requesting additional data 
for the supplemental BLA for the use of 
nivolumab as monotherapy in previously 
untreated patients with BRAF V600 mutation-
positive unresectable or metastatic melanoma. 
Specifi cally, the FDA requested additional 
data in the BRAF-mutated population. The 
manufacturer announced that it is currently 
analyzing additional clinical trial data and 
intends to continue to work with the FDA to 
determine if that data addresses the FDA’s 
request.
Rociletinib (CO-1686)
On Dec. 15, 2015, Clovis Oncology, Inc. 
announced that the FDA extended the PDUFA 
date from March 30, 2016 to June 28, 2016 for 
the review of the NDA for rociletinib for the 
treatment of patients with mutant epidermal 
growth factor receptor (EGFR) non-small cell 
lung cancer who have the EGFR T790M mutation 
and have been previously treated with an 
EGFR-targeted therapy. A major amendment was 
submitted to the FDA on Nov. 16, 2015 to address 
the FDA’s request for additional clinical data for 
both the 500 mg and 625 mg dosing groups. The 
FDA’s Oncologic Drugs Advisory Committee is 
scheduled to review the NDA on April 12, 2016.
*Dates are estimates, current as of 4/6/16, and are subject to change due to any patent litigation or additional patents.
• Kaletra®  (lopinavir/ritonavir)
  12/2016
 
• ProAir® HFA (albuterol sulfate)
  12/2016                                     
 
• Relpax® (eletriptan)
  12/2016
• Zetia® (ezetimibe)
  12/2016
• Azilect® (rasagiline mesylate)
  2/2017
• Tamifl u® (oseltamivir capsules)
  2/2017
• Vytorin® (ezetimibe/
       simvastatin)
  4/2017
• Strattera® (atomoxetine)
  5/2017
• Reyataz® (atazanavir)
  7/2017
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Chorea associated with 
Huntington disease
Teva Pharmaceutical 
Industries
Table Abbreviations: BLA = Biologics License Application, BsUFA = Biosimilar 
User Fee Act, C. diff = Clostridium diffi cile, IV = intravenous, NDA = New 
Drug Application, PDUFA = Prescription Drug User Fee Act, rDNA = ribosomal 
deoxyribonucleic acid, SC = subcutaneous
Deutetrabenazine PDUFA date 5/2016
Primary biliary
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Postmenopausal
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Agents in Clinical Development
Leading Indications with Agents in 
Late-Stage Development
1. Breast cancer
2. Colorectal cancer
3. Non-small cell lung cancer
4. Rheumatoid arthritis
5. Type 2 diabetes mellitus
6. Alzheimer’s disease
7. Prostate cancer
8. Ovarian cancer
9. Pancreatic cancer
10. Pain
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